Kyntra Bio (KYNB)
Develops CD46-targeted cancer therapies and roxadustat for anemia in lower-risk myelodysplastic syndromes.
Something off on this page? Send us feedback.
Develops the FG-3246/FG-3180 CD46 program for prostate cancer and roxadustat for anemia in lower-risk myelodysplastic syndromes. Following the sale of its China operation, it is a single biopharmaceutical development business with roxadustat rights divided by territory.
Develops oncology and anemia therapies through a narrowed clinical pipeline. FG-3246, a CD46-targeting antibody-drug conjugate for metastatic castration-resistant prostate cancer, and the related FG-3180 PET biomarker imaging agent form the oncology program in clinical development. A Phase 2 monotherapy dose-optimization study is under way.
After selling the former China roxadustat operation, operates as a single biopharmaceutical development business based in San Francisco. Roxadustat, approved in Europe, Japan, China, and other markets, is being developed for anemia in lower-risk myelodysplastic syndromes. Commercial rights are divided by territory among the company, AstraZeneca, and Astellas; clinical progress depends on ongoing studies and regulatory processes.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Lake Street | Initiate | Rating: — | |
| Jul 6, 2026 | Oppenheimer | Initiate | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $91.3M · Total debt $0 · Total assets $101.1M · Shareholders' equity −$30.1M
- Revenue
- −$1.5M
- Operating income
- −$17.6M
- Net income
- $12.0M
No dividends on record.
| Insiders | 2.20% | 89.2K shares | |
|---|---|---|---|
| 5 holders · as of Sep 9, 2026 | |||
| Strategic holders | 9.88% | 400.0K shares | |
| 1 holder · as of May 15, 2026 | |||
| Other | 87.92% | 3.56M shares | |
| remainder | |||
4.05M company shares as of Sep 23, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Armistice Capital, LLCStrategic | 9.88% | 400,000 | filed May 15, 2026 |
James A. SchoeneckInsiderdirector | 0.98% | 39,666 | filed Jul 2, 2025 |
Thane WettigInsiderdirector, officer: CEO | 0.66% | 26,796 | filed Sep 9, 2026 |
Christine ChungInsiderofficer: SVP, CHINA OPERATIONS | 0.29% | 11,796 | filed Mar 7, 2025 |
Juan GrahamInsiderofficer: CHIEF FINANCIAL OFFICER | 0.16% | 6,595 | filed Dec 9, 2024 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 14, 2026 | Thane Wettig | director, officer: CEO | +5,600 | $7.09 |
| Nov 13, 2025 | Thane Wettig | director, officer: CEO | +1,000 | $9.18 |
| Nov 17, 2025 | Thane Wettig | director, officer: CEO | +2,700 | $9.10 |
- Bristol-Myers Squibb
Approved LR-MDS anemia therapy with broad first-line use
- Novartis (ADR)
Approved radioligand therapy in PSMA-positive mCRPC
- Geron
Approved telomerase inhibitor for transfusion-dependent LR-MDS anemia
- Johnson & Johnson
Approved PARP-inhibitor combination for BRCA-mutated mCRPC
- Pfizer
Approved PARP-inhibitor and ARPI regimen in HRR-mutated mCRPC
- AstraZeneca (ADR)
Approved PARP-inhibitor regimen for BRCA-mutated mCRPC
- Keros Therapeutics
Phase 2 anemia program for lower-risk MDS
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kyntra Bio | $7.29 | +0.14% | $29.5M | 0.1 | — | 6.4 | −215.4% |
| Bristol-Myers Squibb | $61.51 | −1.19% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Novartis (ADR) | $142.62 | +0.95% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Geron | $1.24 | −5.73% | $840.4M | — | 88.3 | 4.1 | +17.2% |
| Johnson & Johnson | $266.87 | −0.86% | $648.72B | 31.2 | 22.5 | 6.6 | +6.6% |
| Pfizer | $28.18 | +0.88% | $159.19B | 36.9 | 10.1 | 2.5 | +2.6% |
| AstraZeneca (ADR) | $163.68 | −2.79% | $261.12B | 25.3 | 15.4 | 4.3 | +6.4% |
| Keros Therapeutics | $11.60 | −1.11% | $232.6M | — | — | 15.5 | −99.8% |
| Median | 25.3 | 15.3 | 4.3 | +5.7% |